Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
Second interchangeable biosimilar product approved by agency
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Subscribe To Our Newsletter & Stay Updated
